Tuesday, April 05, 2022 12:21:47 PM
Vaccinated Isn’t Enough: Omicron Carries the Risk of Long Covid
https://www.rollingstone.com/culture/culture-commentary/covid-omicron-long-covid-risk-1274717/amp/
https://www.rollingstone.com/culture/culture-commentary/covid-omicron-long-covid-risk-1274717/amp/
On increased immune escape of omicron variant (potentially leading to a lot of symptomatic disease even with prior immunity!) e.g. here:https://t.co/cOFYAMnqCM
— Dr Elisa Perego (@elisaperego78) April 5, 2022
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
